We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-9.15%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.68B
AUM Growth
-$780M
Cap. Flow
-$238M
Cap. Flow %
-14.17%
Top 10 Hldgs %
50.05%
Holding
96
New
8
Increased
9
Reduced
34
Closed
18

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$34.2M
2
VERV
Verve Therapeutics
VERV
+$16.8M
3
VTYX
Ventyx Biosciences
VTYX
+$14.9M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$14M
5
TNGX icon
Tango Therapeutics
TNGX
+$12M

Top Sells

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$50.6M
2
AGEN
Agenus
AGEN
+$25.2M
3
RVMD icon
Revolution Medicines
RVMD
+$20.1M
4
OLMA icon
Olema Pharmaceuticals
OLMA
+$18.7M
5
ASND icon
Ascendis Pharma A/S
ASND
+$17.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMV
76
DELISTED
IMV Inc. Common Shares
IMV
$289K 0.02%
23,437
– –
XFOR icon
77
X4 Pharmaceuticals
XFOR
$460M
$238K 0.01%
3,466
– –
OTLKW
78
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$32K ﹤0.01%
270,698
– –
AGEN
79
Agenus
AGEN
$290M
– –
-244,945
Closed -$25.2M
BPMC
80
DELISTED
Blueprint Medicines
BPMC
– –
-150,000
Closed -$15.4M
DNTH icon
81
Dianthus Therapeutics
DNTH
$6.09B
– –
-29,888
Closed -$3.48M
NBP
82
NovaBridge Biosciences American Depositary Shares
NBP
$202M
– –
-200,000
Closed -$14.5M
INSP icon
83
Inspire Medical Systems
INSP
$1.74B
– –
-48,132
Closed -$11.2M
NERV icon
84
Minerva Neurosciences
NERV
$199M
– –
-11,968
Closed -$167K
OMER icon
85
Omeros
OMER
$959M
– –
-950,000
Closed -$13.1M
TVTX icon
86
Travere Therapeutics
TVTX
$5.78B
– –
-350,000
Closed -$8.49M
VERU icon
87
Veru
VERU
$37.4M
– –
-80,000
Closed -$6.82M
MORF
88
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-100,000
Closed -$5.66M
DMTK
89
DELISTED
DermTech, Inc. Common Stock
DMTK
– –
-300,000
Closed -$9.63M
DCPH
90
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-144,439
Closed -$4.91M
RETA
91
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-100,000
Closed -$10.1M
APTO
92
DELISTED
Aptose Biosciences, Inc.
APTO
– –
-6,667
Closed -$6.54M
TCRR
93
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-479,506
Closed -$4.08M
MYOV
94
DELISTED
Myovant Sciences Ltd.
MYOV
– –
-300,000
Closed -$6.73M
SRNE
95
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-400,000
Closed -$3.05M
QTNT
96
DELISTED
Quotient Limited Ordinary Shares
QTNT
– –
-25,000
Closed -$2.34M
1 2 3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q4 2021 Portfolio in Review

As of Q4 2021, Cormorant Asset Management held 96 positions worth $1.68B, down 32% from $2.46B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Cormorant Asset Management withdrew a net $238M in Q4 2021, closing 18 positions and reducing 34 holdings. Its most notable exit was Agenus, an estimated $25.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Ventyx Biosciences worth $15.1M.

  • Cormorant Asset Management's largest Q4 2021 buy was Ventyx Biosciences: 785,303 shares worth $15.1M.
  • Cormorant Asset Management added most to Beam Therapeutics in Q4 2021, an estimated $34.2M increase.
  • Cormorant Asset Management's biggest Q4 2021 reduction was Atea Pharmaceuticals, cutting an estimated $50.6M.
  • Cormorant Asset Management fully exited Agenus in Q4 2021, selling an estimated $25.2M.
  • Cormorant Asset Management's ten largest holdings make up 50% of its $1.68B portfolio in Q4 2021.
  • Cormorant Asset Management opened 8 new positions and closed 18 in Q4 2021.
  • Cormorant Asset Management's portfolio value fell 32% quarter-over-quarter to $1.68B.

Based on Cormorant Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.